BRL-03

N/A

Report date: 2024/01/16 10:51:16
First In Class

Base Information

Drug NameBRL-03
Drug Alias NameBRL-03BRL03
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursLung NeoplasmsNasopharyngeal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBiosyngen Pte Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Baiji Biopharmaceutical Co LtdBiosyngen Pte Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung NeoplasmsNasopharyngeal Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A